Athira Pharma Inc at Stifel Healthcare Conference Transcript
Well, thanks, everyone, for hanging out for the last fireside chat of the day. Happy to be hosting the Athira management team. I think maybe we can just start by having Mark offer kind of a quick background on the company and where things stand with fosgo, and then we'll do Q&A. So thank you.
Thank you, Paul. So I'm Mark Litton, CEO of Athira. So I'm here with our Chief Operating Officer, Rachel Lenington; and our CMO, Hans Moebius.
For those of you who don't know about Athira, Athira is a late-stage biotech company focused completely on neurodegeneration. Our platform is essentially based on a naturally occurring repair mechanism or the HGF/MET system. And this is a system that's been around for decades. It has neuroprotective characteristics. It's anti-inflammatory. It's been shown to improve the overall survival of nerves, improving cognition as well as function.
And at Athira, we've created a platform of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
